No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Idecabtagene vicleucel demonstrates higher efficacy over currently available therapies in triple-class relapsed and refractory multiple myeloma

byKathleen Lau

July 1, 2021

in StudyGraphics

Epidemiologic analysis of chilblains cohorts before and during the COVID-19 pandemic

RelatedReports

Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial

Weekly Rewinds

New model enhances prediction of prostate cancer-specific mortality

January 12, 2026

2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]

Cardiology

2 Minute Medicine: Pharma Roundup – New oral gonorrhea antibiotic Nuzolvence (zoliflodacin), late‑December cardiovascular and oncology drug approvals, first targeted complement inhibitor therapy for HSCT‑TMA (Yartemlea), and antibody‑drug conjugate (ADC) safety concerns with ifinatamab deruxtecan (I‑DXd) [January 2026]

January 12, 2026

Chronic Disease

High-flow nasal therapy with room air and fan therapy provide modest relief of dyspnea in advanced cancer patients who are not hypoxemic

January 12, 2026

Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation

Sodium-glucose cotransporter 2 inhibitors associated with reduced mortality compared with sulfonylureas in patients with type 2 diabetes

$The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor$

Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

#VisualAbstract Idecabtagene vicleucel demonstrates higher efficacy over currently available therapies in triple-class relapsed and refractory multiple myeloma

2 Minute Medicine Rewind

New model enhances prediction of prostate cancer-specific mortality

Epidemiologic analysis of chilblains cohorts before and during the COVID-19 pandemic

Wellness Check: Sleep

RelatedReports

2 Minute Medicine Rewind

New model enhances prediction of prostate cancer-specific mortality

High-flow nasal therapy with room air and fan therapy provide modest relief of dyspnea in advanced cancer patients who are not hypoxemic

Wellness Check: Sleep

Sodium-glucose cotransporter 2 inhibitors associated with reduced mortality compared with sulfonylureas in patients with type 2 diabetes

Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma

Recent Reports

#VisualAbstract Idecabtagene vicleucel demonstrates higher efficacy over currently available therapies in triple-class relapsed and refractory multiple myeloma

RELATED REPORTS

Epidemiologic analysis of chilblains cohorts before and during the COVID-19 pandemic

Wellness Check: Sleep

RelatedReports

Recent Reports